Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-KAD
- Development stage
- Unknown
- Lead developer
- Livionex
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
C-KAD is a topical ophthalmic drug candidate developed by Livionex for the treatment of early to moderate-stage age-related cataracts. The drug is a proprietary formulation of the metal chelator ethylenediaminetetraacetic acid (EDTA), specifically designed to penetrate the lens of the eye. Its mechanism of action involves targeting and disrupting calcium-lipid-protein aggregates, which are a primary cause of lens clouding and cataract formation. By chelating the calcium ions that stabilize these aggregates, C-KAD aims to dissolve lens opacities and restore transparency, potentially offering a non-surgical therapeutic option for cataract patients. The program has completed Phase 2 clinical trials and is progressing toward Phase 3 development in consultation with the FDA.
- Other names
- C-KAD Eye Drops
Beyond the preview
Go deeper on C-KAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C-KAD.